Technical Analysis for PALI - Palisade Bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.52 | 3.28% | 0.08 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 3.28% | |
| Shooting Star Candlestick | Bearish | 3.28% | |
| Lizard Bearish | Bearish Day Trade Setup | 3.28% | |
| Pocket Pivot | Bullish Swing Setup | 3.28% | |
| Doji - Bearish? | Reversal | 3.28% | |
| Wide Bands | Range Expansion | 3.28% | |
| Inside Day | Range Contraction | 3.70% | |
| Wide Bands | Range Expansion | 3.70% | |
| Outside Day | Range Expansion | 5.44% | |
| Wide Bands | Range Expansion | 5.44% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 2 hours ago |
| Possible Pocket Pivot | about 2 hours ago |
| Down 3% | about 3 hours ago |
| Gap Up Closed | about 3 hours ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/07/2024
Palisade Bio, Inc. Description
Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Surgery Abdominal Pain Gastrointestinal Tract Digestive System
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.35 |
| 52 Week Low | 2.18 |
| Average Volume | 99,681 |
| 200-Day Moving Average | 4.62 |
| 50-Day Moving Average | 3.26 |
| 20-Day Moving Average | 2.76 |
| 10-Day Moving Average | 2.45 |
| Average True Range | 0.32 |
| RSI (14) | 37.50 |
| ADX | 21.4 |
| +DI | 22.85 |
| -DI | 21.15 |
| Chandelier Exit (Long, 3 ATRs) | 2.95 |
| Chandelier Exit (Short, 3 ATRs) | 3.13 |
| Upper Bollinger Bands | 3.56 |
| Lower Bollinger Band | 1.96 |
| Percent B (%b) | 0.3 |
| BandWidth | 58.02 |
| MACD Line | -0.27 |
| MACD Signal Line | -0.27 |
| MACD Histogram | -0.0049 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.25 | ||||
| Resistance 3 (R3) | 3.31 | 3.10 | 3.12 | ||
| Resistance 2 (R2) | 3.10 | 2.89 | 3.07 | 3.07 | |
| Resistance 1 (R1) | 2.77 | 2.77 | 2.94 | 2.71 | 3.02 |
| Pivot Point | 2.56 | 2.56 | 2.64 | 2.53 | 2.56 |
| Support 1 (S1) | 2.23 | 2.35 | 2.40 | 2.17 | 1.86 |
| Support 2 (S2) | 2.02 | 2.23 | 1.99 | 1.81 | |
| Support 3 (S3) | 1.69 | 2.02 | 1.77 | ||
| Support 4 (S4) | 1.63 |
